Photo courtesy of Bayer

Bayer and Dewpoint Therapeutics Partner to Research New Treatments for Cardiovascular and Gynecological Diseases

Originally posted on Bayer.com

Bayer contributes up to USD 100 million / Dewpoint’s drug platform targets biomolecular condensates, dynamic cellular structures newly understood to be central to many disease mechanisms / Biomolecular condensates expand traditional drug target space for small molecules

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to USD 100 million. The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library to develop new treatments for cardiovascular and gynecological diseases.

Today, around 80 percent of the human proteome is still considered to be beyond the reach of small molecules, which make up more than 80 percent of all marketed therapeutic drugs. The emerging paradigm of biomolecular condensates is expanding the traditional drug target space for small molecules by unveiling new targets and new approaches to previously intractable targets.

“As we continue to broaden our capabilities in Research & Development, the collaboration with Dewpoint gives us access to breakthrough innovation potential,” said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development. “New analytic tools and a growing understanding of biomolecular condensates could provide new insights into cellular functions that previously have not been considered by scientists in drug development, enabling us to identify novel pharmacological targets for future therapies.”

Many proteins act as part of complexes in biomolecular condensates, droplet-like membraneless organelles that form dynamically to carry out a wide variety of functions in cells. Though condensates were first observed more than 100 years ago, they have historically been understudied because they are difficult to analyze with traditional drug discovery methods such as protein crystallography and biochemical activity assays. Now, a new wave of research into condensates could provide new insights into cellular function and disease.

“This partnership is an exciting opportunity to advance treatments for diseases that have long evaded the industry. We look forward to combining Bayer’s expertise in chemistry and drug development and Dewpoint’s novel platform and insights into the role of biomolecular condensates in disease,” said Dewpoint CEO Amir Nashat. “We also look forward to working closely with Bayer to expand our capabilities in Germany and put the local biotech ecosystem at the forefront of this important and emerging area.”

Under the terms of the agreement, Bayer will gain the option to exclusively license a specified number of novel therapeutics derived from the research activities. Bayer will contribute with its small molecule compound library and R&D capabilities including high throughput screening and medicinal chemistry. As part of this partnership, Bayer and Dewpoint will broaden Dewpoint’s presence in Germany, and foster local capabilities to translate the emerging science into new medicines.

The collaboration follows Bayer’s participation in Dewpoint’s January 2019 Series A financing round through the Leaps by Bayer unit. The Pharmaceuticals Business Development & Licensing team of Bayer facilitated this collaboration.

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Latest News

Accenture Named a Leader in Automated Life Insurance Underwriting Systems by Independent Research Firm

Originally posted on Accenture.com Accenture has been named a leader in automated life insurance underwriting systems in a new report from independent research firm Forrester. In the report — “The Forrester Wave™: Automated Life Insurance Underwriting Systems, Q4 2019”[1] — Accenture was named a leader based on the current offering and…

AbbVie and Scripps Research Announce Collaboration to Develop a Broad Range of New Therapeutics

Originally posted on Abbvie.com AbbVie, a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology, and fibrosis. “Based on our…

The Hershey Company: Joining Forces to Protect Human Rights

Originally published on thehersheycompany.com by Allison Arbib, Research Program Director at Verité, an independent, nonprofit, civil society organization focused on human rights and eliminating labor abuses.  In a range of human rights and labor rights due diligence frameworks — the UN Guiding Principles, the United States Department of Labor Comply Chain, the…

Comcast Launches Customer Service Program for the Deaf Community in American Sign Language

Originally Published on Comcast.com Comcast and Connect Direct, a subsidiary of Communication Service for the Deaf (CSD), today launched customer service support via American Sign Language (ASL) for Internet Essentials, Xfinity Internet, and general Xfinity billing questions, called ASL Now. With the combined expertise of both companies, Internet Essentials and…